Approximately 1 in 20 adults with outpatient respiratory syncytial virus (RSV) infections were readmitted to the hospital ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

In a few weeks we’ll be a quarter through the current century. It’s a good moment to draw some conclusions. 25 years is a ...

The company finished September with $1.9 billion in cash. A big cash pile gives CRISPR Therapeutics a long runway to ramp up ...

The SPDR XBI exchange traded fund, which tracks an index of small biotech companies, fell more than 10 per cent in the days after Trump’s election and his nomination of Kennedy. It has recovered ...

Abbott Laboratories' revenue and return on invested capital could be more consistent. Read why potential investors will need ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...

By JUDI LUTZ WOODS I am writing in response to the recent commentary “Dedicated Public Servants and Bad Medicine.” In this piece, the authors misled, misinformed, and at times presented totally false ...

If humans can’t undergo such extreme lab tests, then why do animals have to go through such gruesome process? Are they any ...

"It's a real regulatory dilemma here." -- Donald Kohn, MD, of the University of California Los Angeles, at an FDA advisory ...